BDC Bioscience, a Davis, CA-based biotechnology company, raised $12M in Series A funding.
The round was led by Acre Venture Partners, with participation from Seventure Partners iSelect Fund, Collaborative Fund and Skyviews Life Science.
The company intends to use the funds to obtain regulatory approvals for lead products, upscale production capabilities, expand the product pipeline, and to continue to build out the prediction and screening platform.
Founded in 2019 as a spin-out from UC Davis and led by CEO Steve Watkins, BDC Bioscience has developed technology that can produce precision prebiotics from most natural fiber sources and has validated its science platform for rapid screening of prebiotics for precise functional properties, including impact on live biotherapeutics, microbial composition and function, and active metabolites (postbiotics). The platform is also able to deliver deep insights into carbohydrate structure and utilization of prebiotics by bacteria. Commercial applications include foods, nutritionals and therapeutics.